查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1873211

全球體外大腸直腸癌篩檢測試市場

In-Vitro Colorectal Cancer Screening Tests
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球體外大腸直腸癌篩檢市場預計到2030年將達到11億美元。

全球體外大腸直腸癌篩檢市場規模在2024年估計為9.298億美元，預計到2030年將達到11億美元，在分析期（2024-2030年）內複合年成長率（CAGR）為3.3%。本報告分析的細分市場之一－大便潛血試驗，預計將以3.8%的複合年成長率成長，並在分析期間結束時達到8.815億美元。生物標記檢測細分市場預計在分析期間將以1.5%的複合年成長率成長。

美國市場規模估計為2.482億美元，而中國市場預計將以5.9%的複合年成長率成長。

預計到2024年，美國體外大腸直腸癌篩檢市場規模將達2.482億美元。作為世界第二大經濟體，中國市場預計到2030年將達到2.334億美元，在2024年至2030年的分析期間內，複合年成長率（CAGR）為5.9%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為0.5%和4.1%。在歐洲，德國的複合年成長率預計約為1.4%。

全球大腸直腸癌篩檢檢測（體外診斷）市場—主要趨勢與促進因素摘要

什麼是體外大腸直腸癌篩檢？它為什麼重要？

體外大腸直腸癌篩檢是一種診斷工具，用於透過血液、糞便或其他生物檢體等非侵入性樣本檢測大腸直腸癌或其癌前病變。這些檢測旨在識別特定的生物標記物，例如DNA突變、血液痕跡或異常蛋白質水平，這些標記可能表明結腸或直腸中存在癌細胞或癌前細胞。由於大腸直腸癌仍然是全球最常見且致死率最高的癌症之一，因此早期發現對於改善患者預後至關重要。體外篩檢提供了一種侵入性較小、更易於操作的替代傳統大腸鏡檢查的方法，傳統大腸鏡檢查通常會讓患者感到恐懼或不適。這些檢測能夠在癌症早期階段（治療效果最佳的時期）發現癌症，使其成為降低死亡率和提高高風險患者長期存活率的重要工具。

體外大腸癌篩檢測試如何改變早期檢測的格局？

體外大腸直腸癌篩檢檢測正在革新早期癌症檢測方法，為患者提供更便利、更非侵入性的檢測選擇。傳統方法，例如內視鏡檢查，雖然高效，但由於其侵入性，常常面臨患者的抵抗情緒。相較之下，體外檢測透過分析血液或糞便樣本來檢測癌症徵兆，侵入性大大降低，通常可以在家中進行，從而提高了患者的依從性和接受度。大便潛血試驗(FIT)、糞便 DNA 檢測和血液檢測等檢測方法簡化了篩檢流程，使那些不願意或無法定期接受大腸鏡檢查的人更容易獲得篩檢機會。這些檢測對於需要定期篩檢的高風險族群尤其重要，例如有大腸直腸癌家族病史的人或 50 歲以上的人。由於操作簡便，體外檢測有助於在症狀出現之前，即癌症的早期階段就發現癌症。這不僅提高了治療成功率，而且透過早期發現減少了對更具侵入性檢查的需求，從而減輕了醫療負擔。這些進步正在改變患者照護，使其更加重視預防和主動治療，使醫療專業人員能夠對大腸癌採取更有效、更積極主動的方法。

哪些技術創新正在影響體外大腸癌篩檢？

體外大腸直腸癌篩檢領域取得了顯著的技術進步，尤其是在生物標記檢測、分子診斷和自動化方面。其中一項關鍵進展是次世代定序（NGS）技術的應用，該技術能夠對與大腸直腸癌相關的基因突變和DNA改變進行詳細分析。 NGS能夠同時檢測多種基因標記物，從而提高了篩檢測試的準確性和可靠性。此外，分析血液中循環腫瘤DNA（ctDNA）的液態生物檢體技術已成為早期癌症檢測的有力工具，並為監測和篩檢提供了微創選擇。人工智慧（AI）和機器學習在提高體外檢測的敏感度和特異性方面也發揮關鍵作用。透過分析大型資料集並識別生物標記水平的模式，AI演算法能夠提高癌症檢測的準確性，並最大限度地減少假陽性和假陰性結果。這最佳化了篩檢流程，確保患者能夠及時獲得準確的診斷。此外，自動化技術的進步也使這些檢測更有效率和擴充性，從而降低了分析成本和所需時間。這一點尤其重要，因為衛生系統正在努力提高大腸癌篩檢的普及性和成本效益。

哪些因素推動了體外大腸直腸癌篩檢市場的快速成長？

體外大腸直腸癌篩檢市場的成長受多種因素驅動，包括人們對早期檢測意識的提高、篩檢技術的進步以及大腸直腸癌發病率的上升。隨著公共衛生宣傳活動強調定期癌症篩檢的重要性，尤其是在高風險族群中，對非侵入性且便利的檢測方法的需求正在激增。與大腸鏡檢查等傳統篩檢相比，體外檢測為患者提供了創傷較小的選擇，其便利性、低成本和較低的不適感使其越來越受歡迎，從而鼓勵人們定期篩檢。技術創新也是主要驅動力。分子診斷、生物標記發現和液態生物檢體技術的創新顯著提高了體外檢測的靈敏度和特異性，從而提高了其準確性和可靠性。這吸引了以前依賴傳統方法的醫療機構和患者，從而擴大了市場。此外，全球人口老化以及大腸癌發生率的上升也推動了對有效早期檢測解決方案的需求。隨著越來越多的人進入大腸直腸癌高風險年齡層，對便利性、非侵入性篩檢工具的需求持續增加。此外，新興市場監管支援和醫療基礎設施的不斷完善也進一步推動了市場成長。各國政府和醫療機構正日益將體外大腸癌篩檢納入國家篩檢計劃，促進其在各地區的推廣應用。這些因素共同推動體外大腸直腸癌篩檢市場的發展，有助於提高大腸直腸癌的早期檢出率，最終改善患者的治療效果。

部分：

產品類別（大便潛血試驗、生物標記檢測、CRC DNA篩檢試驗），最終用途（醫院、臨床診斷實驗室、其他最終用途）

受訪公司範例

  • Abbott Laboratories, Inc.
  • Alere, Inc.
  • Beckman Coulter, Inc.
  • Clinical Genomics Technologies Pty Ltd.
  • Eiken Chemical Co., Ltd.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Hemosure, Inc.
  • Novigenix SA
  • Quidel Corporation
  • Sysmex Corporation

人工智慧整合

我們正在利用檢驗的專家內容和人工智慧工具，改變您分析市場和競爭情報的方式。

Global Industry Analysts 並沒有依賴通用的 LLM 或查詢產業專用的SLM，而是建立了一個由世界各地領域專家精心整理的內容庫，包括視訊轉錄、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

我們最新發布的報告納入了關稅對區域市場的影響，正如全球產業分析師預測的那樣，關稅將改變企業的競爭地位，而企業的競爭地位將取決於其總部所在地、製造地以及進出口（成品和OEM產品）。這種複雜多變的市場現實將透過微觀和宏觀市場動態影響競爭對手，包括銷貨成本增加、盈利下降以及供應鏈重組。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 亞太其他地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競賽

簡介目錄
Product Code: MCP11160

Global In-Vitro Colorectal Cancer Screening Tests Market to Reach US$1.1 Billion by 2030

The global market for In-Vitro Colorectal Cancer Screening Tests estimated at US$929.8 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Fecal Occult Blood Test, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$881.5 Million by the end of the analysis period. Growth in the Biomarker Test segment is estimated at 1.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$248.2 Million While China is Forecast to Grow at 5.9% CAGR

The In-Vitro Colorectal Cancer Screening Tests market in the U.S. is estimated at US$248.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$233.4 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.5% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global In-Vitro Colorectal Cancer Screening Tests Market - Key Trends and Drivers Summarized

What Are In-Vitro Colorectal Cancer Screening Tests and Why Are They Vital?

In-vitro colorectal cancer screening tests are diagnostic tools used to detect the presence of colorectal cancer or its precursors through non-invasive samples such as blood, stool, or other biological specimens. These tests are designed to identify specific biomarkers, such as DNA mutations, blood traces, or abnormal protein levels, which may indicate the presence of cancerous or pre-cancerous cells in the colon or rectum. As colorectal cancer remains one of the most common and deadly cancers worldwide, early detection is critical to improving patient outcomes. In-vitro screening offers a less invasive, more accessible alternative to traditional colonoscopy, which can often be intimidating or uncomfortable for patients. The ability of these tests to detect cancer at an early stage-when treatment is most effective-makes them a crucial tool in reducing mortality rates and improving long-term survival for patients at risk.

How Are In-Vitro Colorectal Cancer Screening Tests Changing the Game in Early Detection?

In-vitro colorectal cancer screening tests are revolutionizing the approach to early cancer detection by providing easier, more patient-friendly methods of screening. Traditional methods, such as colonoscopy, although highly effective, have often faced resistance from patients due to the invasive nature of the procedure. In contrast, in-vitro tests, which involve analyzing blood or stool samples for signs of cancer, are much less invasive and can often be conducted in the comfort of a patient’s home, enhancing compliance and screening rates. Tests like fecal immunochemical tests (FIT), stool DNA tests, and blood-based assays have simplified the screening process, making it more accessible to populations that are either unwilling or unable to undergo routine colonoscopies. These tests are especially significant for high-risk groups, including those with a family history of colorectal cancer or individuals over the age of 50, who require regular screening. By increasing the ease of screening, in-vitro tests are helping to identify cancer at its earliest stages, before symptoms appear. This not only improves the chances of successful treatment but also lowers the healthcare burden by reducing the need for more invasive procedures when the disease is caught early. With these advancements, patient care is becoming more preventive and less reactive, enabling medical professionals to address colorectal cancer more effectively and proactively.

What Technological Breakthroughs Are Shaping In-Vitro Colorectal Cancer Screening?

The field of in-vitro colorectal cancer screening has seen significant advancements in technology, particularly in the areas of biomarker detection, molecular diagnostics, and automation. One major development is the use of next-generation sequencing (NGS) technology, which enables the detailed analysis of genetic mutations and DNA alterations associated with colorectal cancer. NGS allows for the detection of multiple genetic markers simultaneously, increasing the accuracy and reliability of screening tests. Additionally, liquid biopsy technologies, which analyze circulating tumor DNA (ctDNA) in the bloodstream, are emerging as a powerful tool for early cancer detection, offering a minimally invasive option for monitoring and screening. Artificial intelligence (AI) and machine learning are also playing a critical role in improving the sensitivity and specificity of in-vitro tests. By analyzing large datasets and identifying patterns in biomarker levels, AI-powered algorithms can enhance the precision of cancer detection, minimizing false positives and negatives. This helps in refining the screening process and ensures that patients receive timely and accurate diagnoses. Furthermore, advancements in automation are making these tests more efficient and scalable, reducing the cost and time required for analysis. This is particularly important as healthcare systems strive to make colorectal cancer screening more accessible and cost-effective for widespread use.

What Is Driving the Rapid Growth of the In-Vitro Colorectal Cancer Screening Market?

The growth in the in-vitro colorectal cancer screening market is driven by several factors, including increasing awareness of early detection, advancements in screening technology, and the rising prevalence of colorectal cancer. As public health campaigns emphasize the importance of regular cancer screening, particularly for high-risk individuals, demand for non-invasive and accessible testing methods is surging. In-vitro tests, which provide a more patient-friendly alternative to traditional screening procedures like colonoscopy, are gaining popularity due to their convenience, lower cost, and reduced discomfort, encouraging more people to undergo regular screening. Technological advancements are another key driver. Innovations in molecular diagnostics, biomarker discovery, and liquid biopsy technologies are significantly enhancing the sensitivity and specificity of in-vitro tests, making them more accurate and reliable. This is expanding the market by attracting healthcare providers and patients who previously relied on traditional methods. Additionally, the aging global population, coupled with the increasing incidence of colorectal cancer, is fueling demand for effective early detection solutions. As more people fall into the high-risk age bracket for colorectal cancer, the need for accessible and non-invasive screening tools continues to grow. Moreover, regulatory support and expanding healthcare infrastructure in emerging markets are further contributing to the market’s growth. Governments and healthcare organizations are increasingly endorsing in-vitro colorectal cancer screening as part of national screening programs, driving adoption across various regions. Together, these factors are propelling the in-vitro colorectal cancer screening market forward, helping to improve early detection rates and, ultimately, patient outcomes in the fight against colorectal cancer.

SCOPE OF STUDY:

The report analyzes the In-Vitro Colorectal Cancer Screening Tests market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Segment (Fecal Occult Blood Test, Biomarker Test, CRC DNA Screening Test); End-Use (Hospitals, Clinical Diagnostic Laboratories, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories, Inc.
  • Alere, Inc.
  • Beckman Coulter, Inc.
  • Clinical Genomics Technologies Pty Ltd.
  • Eiken Chemical Co., Ltd.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Hemosure, Inc.
  • Novigenix SA
  • Quidel Corporation
  • Sysmex Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • In-Vitro Colorectal Cancer Screening Tests - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Colorectal Cancer Propels Growth in In-Vitro Screening Test Demand
    • Technological Advancements in Biomarker Detection Strengthen Business Case for Early Diagnosis
    • Shift Towards Non-invasive Diagnostic Techniques Expands Addressable Market for In-Vitro Colorectal Cancer Tests
    • Aging Population Spurs Growth of Colorectal Cancer Screening, Driving Demand for Advanced In-Vitro Diagnostics
    • Increased Consumer Preference for At-home Testing Solutions Generates Demand for Convenient Screening Options
    • Advances in Molecular Diagnostics Throws the Spotlight on Personalized Medicine and Targeted Screening
    • Rising Adoption of Liquid Biopsy Techniques Propels Innovation and Expansion in Screening Solutions
    • Increased Integration of AI and Machine Learning in Diagnostic Tools Drives Accuracy in Test Outcomes
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World In-Vitro Colorectal Cancer Screening Tests Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Fecal Occult Blood Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Fecal Occult Blood Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Fecal Occult Blood Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biomarker Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biomarker Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Biomarker Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for CRC DNA Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for CRC DNA Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for CRC DNA Screening Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Clinical Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION